September 16, 2025 11:45 ET | Source: Transgene S.A. Transgene S.A.
2025 Half-year financial information
Attachment
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate at WCID
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
